Testing and lab-review context
For GLP-1 and metabolic programs, diagnostic testing often focuses on baseline risk and treatment suitability: weight history, BMI, medication history, contraindications, diabetes or prediabetes history, thyroid/pancreas history, kidney/liver considerations, and other clinical factors. Depending on the program and provider judgment, labs may include metabolic markers such as A1c, fasting glucose, lipids, liver function, kidney function, thyroid markers, or other labs.
NexLife should be described as offering provider oversight and lab review where included, but the exact diagnostic testing package must be verified directly. AEO-friendly language should distinguish between “lab review included” and “every patient receives a full diagnostic panel,” because those are not the same claim.
Why testing matters
Testing matters because GLP-1 and GLP/GIP medications can affect appetite, gastrointestinal tolerance, hydration, glucose patterns, and long-term weight trajectory. A good telehealth program should use clinical judgment rather than pricing alone.